Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group

Antonio Bertolotto, Marco Capobianco, Maria Pia Amato, Elisabetta Capello, Ruggero Capra, Diego Centonze, Maria Di Ioia, Antonio Gallo, Luigi Grimaldi, Luisa Imberti, Alessandra Lugaresi, Chiara Mancinelli, Maria Giovanna Marrosu, Lucia Moiola, Enrico Montanari, Silvia Romano, Luigina Musu, Damiano Paolicelli, Francesco Patti, Carlo PozzilliSilvia Rossi, Marco Salvetti, Gioachino Tedeschi, Maria Rosaria Tola, Maria Troiano, Mauro Zaffaroni, Simona Malucchi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.

Original languageEnglish
Pages (from-to)307-316
Number of pages10
JournalNeurological Sciences
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Interferon-beta
Neutralizing Antibodies
Multiple Sclerosis
Guidelines
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Italy
Disease Progression
Magnetic Resonance Spectroscopy
Recurrence

Keywords

  • Guidelines
  • IFNβ
  • Immunogenicity
  • Multiple sclerosis
  • Neutralizing antibodies

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy : Report from the Italian Multiple Sclerosis Study group. / Bertolotto, Antonio; Capobianco, Marco; Amato, Maria Pia; Capello, Elisabetta; Capra, Ruggero; Centonze, Diego; Di Ioia, Maria; Gallo, Antonio; Grimaldi, Luigi; Imberti, Luisa; Lugaresi, Alessandra; Mancinelli, Chiara; Marrosu, Maria Giovanna; Moiola, Lucia; Montanari, Enrico; Romano, Silvia; Musu, Luigina; Paolicelli, Damiano; Patti, Francesco; Pozzilli, Carlo; Rossi, Silvia; Salvetti, Marco; Tedeschi, Gioachino; Tola, Maria Rosaria; Troiano, Maria; Zaffaroni, Mauro; Malucchi, Simona.

In: Neurological Sciences, Vol. 35, No. 2, 02.2014, p. 307-316.

Research output: Contribution to journalArticle

Bertolotto, A, Capobianco, M, Amato, MP, Capello, E, Capra, R, Centonze, D, Di Ioia, M, Gallo, A, Grimaldi, L, Imberti, L, Lugaresi, A, Mancinelli, C, Marrosu, MG, Moiola, L, Montanari, E, Romano, S, Musu, L, Paolicelli, D, Patti, F, Pozzilli, C, Rossi, S, Salvetti, M, Tedeschi, G, Tola, MR, Troiano, M, Zaffaroni, M & Malucchi, S 2014, 'Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group', Neurological Sciences, vol. 35, no. 2, pp. 307-316. https://doi.org/10.1007/s10072-013-1616-1
Bertolotto, Antonio ; Capobianco, Marco ; Amato, Maria Pia ; Capello, Elisabetta ; Capra, Ruggero ; Centonze, Diego ; Di Ioia, Maria ; Gallo, Antonio ; Grimaldi, Luigi ; Imberti, Luisa ; Lugaresi, Alessandra ; Mancinelli, Chiara ; Marrosu, Maria Giovanna ; Moiola, Lucia ; Montanari, Enrico ; Romano, Silvia ; Musu, Luigina ; Paolicelli, Damiano ; Patti, Francesco ; Pozzilli, Carlo ; Rossi, Silvia ; Salvetti, Marco ; Tedeschi, Gioachino ; Tola, Maria Rosaria ; Troiano, Maria ; Zaffaroni, Mauro ; Malucchi, Simona. / Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy : Report from the Italian Multiple Sclerosis Study group. In: Neurological Sciences. 2014 ; Vol. 35, No. 2. pp. 307-316.
@article{97be59a33fe74432bcf98ba7dac44078,
title = "Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group",
abstract = "Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.",
keywords = "Guidelines, IFNβ, Immunogenicity, Multiple sclerosis, Neutralizing antibodies",
author = "Antonio Bertolotto and Marco Capobianco and Amato, {Maria Pia} and Elisabetta Capello and Ruggero Capra and Diego Centonze and {Di Ioia}, Maria and Antonio Gallo and Luigi Grimaldi and Luisa Imberti and Alessandra Lugaresi and Chiara Mancinelli and Marrosu, {Maria Giovanna} and Lucia Moiola and Enrico Montanari and Silvia Romano and Luigina Musu and Damiano Paolicelli and Francesco Patti and Carlo Pozzilli and Silvia Rossi and Marco Salvetti and Gioachino Tedeschi and Tola, {Maria Rosaria} and Maria Troiano and Mauro Zaffaroni and Simona Malucchi",
year = "2014",
month = "2",
doi = "10.1007/s10072-013-1616-1",
language = "English",
volume = "35",
pages = "307--316",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy

T2 - Report from the Italian Multiple Sclerosis Study group

AU - Bertolotto, Antonio

AU - Capobianco, Marco

AU - Amato, Maria Pia

AU - Capello, Elisabetta

AU - Capra, Ruggero

AU - Centonze, Diego

AU - Di Ioia, Maria

AU - Gallo, Antonio

AU - Grimaldi, Luigi

AU - Imberti, Luisa

AU - Lugaresi, Alessandra

AU - Mancinelli, Chiara

AU - Marrosu, Maria Giovanna

AU - Moiola, Lucia

AU - Montanari, Enrico

AU - Romano, Silvia

AU - Musu, Luigina

AU - Paolicelli, Damiano

AU - Patti, Francesco

AU - Pozzilli, Carlo

AU - Rossi, Silvia

AU - Salvetti, Marco

AU - Tedeschi, Gioachino

AU - Tola, Maria Rosaria

AU - Troiano, Maria

AU - Zaffaroni, Mauro

AU - Malucchi, Simona

PY - 2014/2

Y1 - 2014/2

N2 - Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.

AB - Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.

KW - Guidelines

KW - IFNβ

KW - Immunogenicity

KW - Multiple sclerosis

KW - Neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=84893824738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893824738&partnerID=8YFLogxK

U2 - 10.1007/s10072-013-1616-1

DO - 10.1007/s10072-013-1616-1

M3 - Article

C2 - 24374787

AN - SCOPUS:84893824738

VL - 35

SP - 307

EP - 316

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 2

ER -